Immune-modulatory approaches involving T-cell transfer, natural killer T-cell (NKT) activators and interferon-gamma (IFN-γ) have shown benefit in reducing post-stroke immunosuppression (Wong et al., 2011; Liu et al., 2017). Here, IFNG is linked to stroke disorder.